Thymulin

Bordigoni P, Faure G, Bene MC, Dardenne M, Bach JF, et al. (1982, Lancet): synthetic thymulin administered to children with primary immunodeficiency disorders. The treatment produced improvements in cellular immunity markers and IgA production. This study represents the total published controlled evidence for exogenous thymulin administration in humans. The limitations: case series design (no randomized comparison); immunodeficient children with primary T-cell deficiency (not aging adults with age-related immunosenescence, which is the community application); no follow-up or replication in 40+ years. Grade D — single uncontrolled case series in a non-representative population from 1982 with no replication.

THE HUMAN EVIDENCE GAP — THE MOST HONEST STATEMENT IN THIS CHAPTER

There are no published randomized controlled trials of exogenous thymulin administration in humans for any indication. The only published human interventional data is a 1982 Lancet case series in immunodeficient children — 43 years old, uncontrolled, in a completely different population from the community users who inject thymulin for age-related immune support. The animal evidence for thymulin's immunological, anti-inflammatory, and analgesic effects is extensive and interesting. The mechanistic biology is real. The translation to controlled human outcomes has never been attempted in a modern clinical trial format. Community users of injectable thymulin are self-administering based entirely on: (1) animal model data; (2) mechanistic reasoning; (3) a 43-year-old uncontrolled case series. This is the lowest human evidence grade (Grade D-E) of any endogenous thymic peptide in this book.

The animal evidence for thymulin is extensive and covers multiple biological domains: Immunological restoration: thymectomized animals receiving thymulin show partial restoration of T-cell function; old mice with low thymulin activity show improved immune responses after thymulin administration; zinc supplementation (restoring endogenous Zn-thymulin) shows comparable effects to exogenous thymulin in many models — consistent with the zinc-mediated mechanism. Anti-inflammatory/analgesic: Nasseri 2019 and related studies: thymulin injection reduces inflammatory pain markers; NF-κB/cytokine pathway suppression in spinal cord; grade C evidence for analgesic effects in well-characterized animal pain models. Lung disease: thymulin modulation in experimental pulmonary inflammation reduces lung injury markers; grade C. Neuroprotection: BBB protection in MS-like animal models; grade D. Gene therapy: AAV-thymulin produces lasting anti-inflammatory effects in arthritis models; grade C (preclinical).

Application

Grade

Best Evidence

The Honest Assessment

T-cell maturation biology (mechanism)

A

Decades of animal/mechanistic data; Bach's foundational work

Mechanism established; clinical translation in humans not proven

Zinc supplementation restoring active thymulin (in deficient adults)

B

Mocchegiani 1995; Prasad 1988 JCI (zinc depletion/repletion human study)

Grade B for zinc — the most evidence-supported thymulin-related intervention

Exogenous thymulin in humans (any indication)

D

Bordigoni 1982 Lancet (case series, immunodeficient children, n small)

One 43-year-old uncontrolled study. No replication. No RCT ever completed.

Anti-inflammatory/analgesic (animal models)

C-D

Nasseri 2019 Int Immunopharmacol; Safieh-Garabedian et al.

Animal data; no human trial; interesting mechanistic direction

Neuroprotection

D

2023 MS model; in vitro neuroinflammation data

Preliminary animal/in vitro; far from clinical application

Gene therapy (AAV-thymulin, animal models)

C

Multiple AAV gene therapy animal studies

Most scientifically rigorous current direction; purely preclinical

Community use: aging immune support

E

No controlled evidence in this population

Grade E — mechanistically plausible; zinc optimization is the better-evidenced alternative

Thymulin: 9 amino acids. Sequence: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. The N-terminal glutamic acid is a pyroglutamate (pGlu) — cyclized to form a pyrrolidone ring rather than the typical free amino acid terminus. This pyroglutamate modification provides partial protection against aminopeptidase degradation. MW approximately 858.86 Da. CAS 63958-90-7. The peptide is water-soluble, small, and unlike many larger peptides, relatively accessible to cellular receptors without complex delivery requirements. Synonyms: serum thymic factor (FTS), facteur thymique sérique.

THE ZINC ACTIVATION MECHANISM — THE DEFINING PHARMACOLOGICAL PROPERTY

Thymulin exists in two forms in vivo: APO-THYMULIN (zinc-free, inactive): pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn in its free peptide conformation. Cannot interact with thymulin receptors with sufficient affinity to trigger signaling. Circulates in blood but produces no immunological effect. ZN-THYMULIN (zinc-bound, active): Thymulin complexed with Zn²⁺ in a 1:1 equimolar ratio. Zinc binding induces a specific three-dimensional conformation confirmed by NMR studies — the histidine (position 3, lysine), serine, and glutamine residues coordinate the zinc ion in a specific geometry that creates the receptor-binding face. This conformation is the active drug. The transition from apo-thymulin to Zn-thymulin depends entirely on zinc availability: in zinc-sufficient environments, thymulin is predominantly in the active Zn-bound form; in zinc-deficient environments, thymulin circulates predominantly as inactive apo-thymulin. This is NOT a subtle pharmacological detail — it means that measuring serum 'thymulin' levels without specifically assaying the active zinc-bound form gives a meaningless result. Only active Zn-thymulin measurements matter clinically.

Thymulin is produced exclusively by thymic epithelial cells (TECs) — the specialized cells that form the three-dimensional architecture of the thymus and provide the microenvironment for T-cell development. TECs secrete thymulin in its active zinc-bound form: immunohistochemistry shows zinc and metallothionein (a zinc-storage protein) are co-expressed within the TEC cytoplasm alongside thymulin, confirming that the zinc is incorporated into thymulin during or before secretion. This means TECs don't produce inactive apo-thymulin that becomes activated elsewhere — they produce the active metallopeptide and release it into circulation. The apo-thymulin that accumulates in zinc-deficient states is active Zn-thymulin that has lost its zinc to the deficiency-driven redistribution of body zinc pools.

The thymus reaches peak size (approximately 30-40 grams) in early childhood and involutes progressively from puberty under sex hormone influence. By age 40-50, most thymic parenchyma is replaced by adipose tissue; by age 70-80, functional thymic epithelial mass is reduced to a small fraction of peak. As TEC mass declines, total thymulin production capacity declines. This structural component of thymulin decline is real and produces genuine reduction in thymulin synthesis — not just in zinc-bound activity. Restoring this component requires either thymic regeneration strategies (the subject of ongoing longevity research), exogenous thymulin administration, or living with reduced thymic output. This is the component the community attempts to address with injectable thymulin.

Zinc deficiency is prevalent in elderly adults — estimated 30-40% of adults over 65 are zinc-deficient based on multiple population surveys. Causes: reduced dietary zinc intake; impaired intestinal zinc absorption with age; medications that deplete zinc (ACE inhibitors, thiazide diuretics); increased zinc requirements in disease states. In zinc-deficient states: zinc is redistributed from low-priority to high-priority compartments; blood zinc falls; the zinc-binding capacity for thymulin is reduced; circulating active Zn-thymulin partially de-metalates to inactive apo-thymulin. The result: measured thymulin activity falls — but this component of the fall is not due to reduced TEC production of thymulin; it is due to loss of the cofactor that activates the peptide. This component is completely reversible with zinc supplementation.

Mocchegiani et al. (1995): oral zinc supplementation (15 mg/day) in elderly subjects — both zinc-deficient and borderline zinc-deficient — significantly restored active serum thymulin levels and NK cell cytotoxic function. The timeline: partial restoration at 1-3 months; maximum restoration at 6 months of supplementation. The mechanism: existing circulating apo-thymulin in the blood becomes remetallated as plasma zinc rises — the peptide is still there, produced by TECs and circulating; it just needed zinc to become active. In zinc-sufficient elderly individuals: supplementation did NOT increase thymulin above normal levels. This ceiling confirms that the benefit is purely deficiency correction, not supraphysiological enhancement. The Prasad 1988 JCI study with experimental zinc depletion in human volunteers showed both the depletion (reduced thymulin, reduced T-cell markers, reduced IL-2) and the reversal (zinc repletion restored all parameters). This is Grade B human evidence for zinc as a thymulin restoration strategy in deficient individuals.

The most evidence-based first step for any individual considering thymulin for age-related immune support: assess zinc status. Testing: serum zinc (most accessible; lower sensitivity); plasma zinc (slightly better); erythrocyte zinc (better indicator of chronic status); taste test (informal; reduced taste acuity is a symptom of zinc deficiency). Reference ranges: serum zinc normal 70-120 μg/dL; below 70 μg/dL suggests deficiency. Intervention: zinc supplementation at 15-25 mg/day of elemental zinc (as zinc picolinate, zinc glycinate, or zinc bisglycinate for absorption; not zinc oxide — poor bioavailability). Duration: 3-6 months to maximize thymulin restoration. Cost: pennies per day. Risk: negligible at 15-25 mg/day (far below the 40 mg/day upper limit for adults). Evidence grade: B for zinc supplementation in deficient adults. Compare this to: Grade D for exogenous thymulin injection in humans (one 1982 case series). The rational order is: correct zinc deficiency first, then re-evaluate whether exogenous thymulin is needed.

The zinc-thymulin relationship is not isolated from the broader hormonal context of aging. Mocchegiani et al. 2013 demonstrated that thymic involution is secondary to age-related disruptions in neuroendocrine signaling rather than an intrinsic thymic failure — and that thymic function and even thymic regrowth could be restored in old mice through endocrinological interventions (melatonin, arginine, zinc). This neuroendocrine-thymic connection has several practical implications: (1) melatonin supplementation — which declines dramatically with aging — has been shown to partially restore thymic function and thymulin production in aging rodents, providing another inexpensive nutritional/supplemental approach to the structural component of thymulin decline; (2) growth hormone and IGF-1 (which decline with somatopause) also support thymic epithelial cell function and thymulin production; GH secretagogue therapy may thus partly restore thymulin production through the structural pathway; (3) the thymus is an endocrine-responsive organ that can be partially regenerated by addressing the neuroendocrine decline that drives its involution. This broader context suggests that the multi-pronged longevity approach (zinc, melatonin, GH secretagogue support, vitamin D for Tα1 production) may provide more thymic immune benefit than isolated thymulin injection.

Thymulin (Zn-thymulin) binds high-affinity receptors on thymocytes and T-lymphocytes at the CD71/transferrin receptor complex and possibly other thymocyte surface proteins. Downstream signaling: PKA pathway activation → transcription factor modulation → induction of T-cell surface marker expression (CD2, CD3, CD4, CD8, T-cell receptor components); promotes thymocyte differentiation from double-negative (CD4-CD8-) precursors toward single-positive (CD4+ helper or CD8+ cytotoxic) mature T-cells; restores T-cell surface marker expression in thymectomized animals — the original assay used to characterize thymulin. Additionally: promotes regulatory T-cell (Treg) development; modulates CD4+/CD8+ ratio; enhances suppressor T-cell function (noted by Bach in early papers as the most remarkable effect and the first predicted to find clinical application). The T-cell maturation biology is well-established in animal models. Whether exogenous thymulin administration replicates these effects in human clinical contexts is not established by controlled trials.

Safieh-Garabedian et al. and Nasseri et al. (2019, International Immunopharmacology) documented a thymulin mechanism that extends beyond classical thymic immunology into neuroinflammation and pain: thymulin treatment in animal models of inflammatory pain reduces spinal cord NF-κB activation and pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) at the spinal level. The consequence: reduced mechanical allodynia and thermal hyperalgesia (pain sensitivity) in animal models of inflammatory arthritis and peripheral inflammation. The mechanism appears to involve thymulin's ability to dampen TLR4-NF-κB signaling in spinal microglia and astrocytes, reducing the central sensitization that amplifies inflammatory pain signals. This anti-nociceptive effect is mechanistically distinct from thymulin's classical T-cell maturation function and represents a neuroimmune modulation pathway that has attracted recent research interest.

Emerging evidence from animal and in vitro studies suggests thymulin may protect the central nervous system through anti-inflammatory mechanisms in glial cells. A 2023 study demonstrated that thymulin combined with peroxiredoxin 6 showed protective effects on the blood-brain barrier in an experimental multiple sclerosis model. Additional in vitro data suggest thymulin reduces microglial activation and neuroinflammation, potentially complementing the LDN and other anti-neuroinflammatory approaches. These findings are Grade D — preliminary and not replicated in controlled human studies.

The most active current research direction for thymulin involves not administering the peptide directly but delivering the gene encoding thymulin via recombinant viral vectors (AAV — adeno-associated virus). In animal models of rheumatoid arthritis, inflammatory pain, and fibromyalgia-like conditions: AAV-thymulin gene transfer to skeletal muscle produces sustained local thymulin expression; sustained thymulin production from the muscle depot provides long-lasting anti-inflammatory and anti-nociceptive effects. This gene therapy approach bypasses the challenges of short peptide half-life and frequent dosing that limit direct thymulin administration. It is purely preclinical as of 2026 but represents the most scientifically serious current thymulin research.

Santos et al. (2010, Expert Opinion on Therapeutic Targets) reviewed thymulin's immunomodulatory role in lung diseases, documenting that thymulin modulates pulmonary immune responses and reduces inflammatory markers in experimental lung injury models. Thymulin receptors are expressed on pulmonary epithelial cells and alveolar macrophages, providing a mechanistic basis for pulmonary anti-inflammatory effects beyond its classical thymic T-cell role. In chronic lung disease models, thymulin reduces neutrophil-dominated inflammatory infiltrates and cytokine storms. These findings are interesting for potential applications in conditions like asthma, COPD, and acute respiratory distress — but no human clinical trial has been completed. Grade C — animal data; no human controlled evidence.

Compound

Type

Primary Mechanism

Human Evidence Grade

Regulatory Status

Key Differentiator

Thymosin Alpha-1 (Tα1)

28-aa synthetic derived from prothymosin alpha

TLR2/TLR9 on DCs → Th1/NK/IDO/Treg; bidirectional immunomodulator

A (HBV meta-analysis RR 2.31; multiple RCTs)

Approved 37+ countries (Zadaxin); US: Category 2 → removed → PCAC pending

Strongest clinical evidence of any thymic peptide; used as cancer adjunct

Thymulin

9-aa zinc-dependent endogenous thymic hormone

Zn-thymulin → thymocyte receptor → T-cell maturation; NF-κB anti-inflammatory

D (one 1982 Lancet case series)

Research chemical; no approval anywhere

Only thymic hormone requiring metal cofactor; zinc deficiency correction is the practical intervention

Thymalin

Complex mixture of short thymic bioregulator peptides (Khavinson)

Multiple short peptides → epigenetic gene expression restoration; transcriptional regulation

C (Soviet clinical series; limited Western replication)

Russia: approved as drug; research chemical elsewhere

Complex mixture; different scientific tradition; Khavinson cluster chapter covers this

TB-500 (Tβ4 fragment)

43-aa tissue repair; NOT thymic immune modulation

G-actin sequestration; wound healing; cardiac protection; angiogenesis

C-D (animal + limited human trial data)

Research chemical; no approval

Shares the 'thymosin' name only; completely different mechanism; repair peptide not immune peptide

The practical comparison for the community user considering thymulin: Thymosin Alpha-1 has the strongest controlled clinical evidence of any thymic peptide, is approved in 37+ countries, and has been used in hundreds of thousands of patients in its approved indications. It is the appropriate choice for evidence-based thymic immune support. Thymulin is interesting mechanistically, has the zinc biology as a practical nutritional optimization target, but has essentially no controlled human clinical evidence for the injectable application. The hierarchy of evidence strongly favors Tα1 over thymulin for the immune optimization application — if the goal is thymic support with established evidence.

Thymulin's safety profile in humans is essentially uncharacterized by modern standards — there is simply no substantial human clinical trial database to draw from. The 1982 Bordigoni Lancet case series reported no significant adverse effects. Animal toxicology: no reported dose-limiting toxicity at therapeutic doses in animal studies; no organ toxicity; no HPTA effects. Theoretical safety considerations: thymulin promotes T-cell differentiation, which creates the same theoretical concern as any immune-activating compound in autoimmune disease and active malignancy contexts. The bidirectional regulatory T-cell promotion (thymulin specifically enhances suppressor T-cell function in Bach's original characterization) provides some theoretical reason to be less concerned about autoimmune exacerbation than with pure Th1-activating compounds — Treg induction is tolerogenic. But the lack of human data means safety is genuinely unknown for chronic injectable use.

For exogenous thymulin to have any biological activity, adequate zinc must be present. Community users injecting thymulin without ensuring adequate zinc are potentially administering an inactive compound. The practical protocol: ensure adequate zinc status before and during thymulin use. Target: serum zinc 80-120 μg/dL. Supplementation: 15-25 mg/day elemental zinc. Forms: zinc picolinate, zinc glycinate, zinc bisglycinate (good absorption); avoid zinc oxide (poor bioavailability). Monitoring: symptom assessment for zinc deficiency (reduced taste/smell acuity, immune dysfunction, hair loss, slow wound healing); periodic serum zinc testing if concerned. Timing: zinc supplementation alongside or before thymulin for maximum activation.

Thymulin promotes T-cell maturation and NK cell activity — immune activation effects that carry the generic active malignancy concern applicable to all immune-activating compounds. Unlike LL-37, where specific pro-tumor mechanisms are documented for specific cancer types, thymulin's cancer pharmacology is less specifically characterized. Thymulin's enhancement of regulatory T-cell (Treg) activity could theoretically suppress tumor immunity rather than promote it — Tregs are immunosuppressive and can protect tumor cells from immune attack. Whether thymulin's net effect is pro-tumor or anti-tumor in specific oncological contexts has not been studied. Active malignancy: physician/oncologist consultation before use. The generic caution applies; the compound-specific risk is not characterized.

No validated human dosing protocol exists for exogenous thymulin. The community doses cited in vendor literature and forum discussions are extrapolations from animal study doses adjusted for body weight — not human pharmacokinetic or pharmacodynamic studies. Most common cited community protocols: 20-40 mcg SubQ, once daily or 2-3x weekly. These numbers have no human evidence basis. They appear to be derived from rat dosing studies (approximately 100-200 μg/kg in rats) scaled to human body weight. Whether these doses produce meaningful thymulin receptor engagement in humans, produce adequate plasma thymulin concentrations, or have any pharmacological effect at all is unknown.

Sharing the 'thymic' origin does not mean pharmacological equivalence. Thymosin Alpha-1 (28 amino acids) activates TLR2/TLR9 on dendritic cells → Th1 polarization, NK activation, IDO-mediated Treg calibration. It has Grade A evidence in HBV and is approved in 37+ countries. Thymulin (9 amino acids, zinc-dependent) acts on thymocyte receptors to promote T-cell maturation. It has Grade D human evidence and no regulatory approval. They act through completely different receptors and mechanisms. Tα1's evidence base is approximately 100x larger than thymulin's. They are not interchangeable.

Low active thymulin levels with aging have two components: structural (thymic involution) and functional (zinc deficiency). Before concluding that injectable thymulin is needed, assess zinc status. If zinc-deficient (common in 30-40% of adults over 60), zinc supplementation will restore active thymulin bioactivity more effectively than injecting thymulin without adequate zinc. After zinc optimization, re-evaluate. The injectable thymulin only addresses the structural component — and has no controlled human evidence even for that application.

These are opposite errors. Thymulin is not zinc — it is a peptide that requires zinc as a cofactor. Zinc is not thymulin — it activates existing apo-thymulin in the body but does not itself provide thymulin's receptor signaling. The relationship: zinc is necessary but not sufficient for thymulin activity; thymulin is necessary but not sufficient without zinc. Zinc supplementation restores the functional form of the compound the body already produces — it does not add a new signaling molecule.

TB-500 (Thymosin Beta-4 fragment) is a tissue repair peptide that works through G-actin sequestration and actin dynamics. It has nothing to do with thymic immune function. It was named 'thymosin beta-4' because it was isolated from thymic tissue in the 1960s — not because it promotes T-cell development. Thymulin promotes T-cell maturation. They share nothing except having been isolated from thymic preparations. They cannot be used interchangeably for any purpose.

Bach JF, Dardenne M, Pleau JM, Rosa J. (1977). Biochemical characterisation of a serum thymic factor. Nature. 266(5597):55-57. PMID 557350. [The original thymulin isolation; Nature publication; establishment of FTS as a thymic hormone with immunological activity. The foundational paper.]

Dardenne M, Pleau JM, Nabarra B et al. (1982). Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proceedings of the National Academy of Sciences. 79(17):5370-5373. [Zinc requirement for thymulin bioactivity established; metallopeptide characterization; NMR confirmation of zinc-induced conformation.]

Prasad AS, Meftah S, Abdallah J et al. (1988). Serum thymulin in human zinc deficiency. Journal of Clinical Investigation. 82(4):1202-1210. PMID 3262625. [Experimental zinc depletion in human volunteers reduces thymulin activity; zinc repletion restores it; T-cell subpopulation changes correlate; the foundational human zinc-thymulin relationship study.]

Mocchegiani E, Muzzioli M, Giacconi R. (2000). Zinc, metallothioneins, immune responses, survival and ageing. Biogerontology. 1(2):133-143. [Zinc supplementation in elderly subjects restores thymulin bioactivity and NK cell function; 15 mg/day protocol; 1-6 month timeline; the key zinc restoration reference.]

Bordigoni P, Faure G, Bene MC, Dardenne M, Bach JF, Duheille J, and Olive D. (1982). Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS). Lancet. 2(8298):293-297. [The only published human interventional study for exogenous thymulin; immunodeficient children; improved cellular immunity; 43 years old; no replication. The complete human clinical evidence base for injectable thymulin.]

Nasseri B, Amin Sadeghi B, Arshadi S, Emamgholipour S, Khalesi S. (2019). Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways. International Immunopharmacology. [Animal model; thymulin reduces spinal NF-κB, IL-1β, IL-6; anti-nociceptive effects; Grade C animal evidence for analgesic properties.]

Reggiani PC, Morel GR, Cónsole GM, Goya RG. (2009). The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin. Annals of the New York Academy of Sciences. 1153:98-106. [Comprehensive review of thymulin biology including neuroendocrine interactions, aging effects, and therapeutic directions.]

• Step 1 — Zinc assessment: serum zinc; target 80-120 μg/dL; supplement with 15-25 mg/day elemental zinc if deficient; reassess thymulin function after 3-6 months. This is where most people should stop.
• Step 2 — Zinc-sufficient and still want thymulin: Grade D human evidence; mechanistically coherent; animal data positive; low apparent risk; co-administer with zinc to ensure peptide activation; community doses 20-40 mcg SubQ.
• Evidence-based thymic immune support instead: consider Thymosin Alpha-1 (Grade A HBV; Grade B MS; approved 37+ countries); far superior evidence base for the thymic immune support goal.
• Active malignancy: physician/oncologist consultation required; immune activation mechanism applies; risk profile not specifically characterized for thymulin.
• Autoimmune disease: thymulin's Treg-promoting activity provides theoretical rationale for potential tolerance effects; no controlled evidence; physician supervision required.

— End of Thymulin —

THE PEPTIDE BIBLE | Thymulin | For Research & Educational Purposes Only